drugset / Trial / NCT01225341

Botulinum Toxin A for Herpes Labialis

NCT01225341

Terminated 20 enrolled DeNova Research Allergan · collab
RandomizedCrossoverDouble-blindPrevention

Summary

The purpose of this study is to determine the efficacy and safety of Botulinum Toxin Type A as a preventative measure for Herpes Labialis.

Timeline

Start
2010-08
Primary completion
2012-05
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 8 iu Intramuscular

Indications